Though it is still early on, rocbrutinib appears to be effective in CLL patients with prior BTKi resistance mutations, and it is generally well-tolerated.
The BTK degrader BGB-16673 shows promise in relapsed CLL. By degrading or destroying BTK instead of blocking it, degraders may overcome resistance.
Pirtobrutinib provides longer progression-free survival and is safer than idelalisib-rituximab and bendamustine-rituximab for treating relapsed CLL.
Join CLL Society and Dr. Deborah Stephens to learn how a comprehensive approach to well-being can complement your CLL care.
MEDICINE CABINET: MEDICATION SIDE EFFECTS Download and Print This Medication Sheet Many common side effects can occur with any of the chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) drugs.
When diagnosed with chronic lymphocytic leukemia (CLL), doctors should pause and help patients understand the watch and wait period.
Epcoritamab, a novel bispecific antibody monotherapy, showed strong results in relapsed / refractory high-risk CLL patients.
CLL Symptoms In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice,
Regular blood testing for those with CLL and SLL is an important part of managing the disease, as it can provide valuable insights into your overall health.
